HeartWare International, Inc. Announces Completion of Public Offering of Common Stock
FRAMINGHAM, Mass. and SYDNEY, Feb 02, 2010 /PRNewswire via COMTEX/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN) ("HeartWare") announced today the completion of a public offering of 1,767,900 shares of its common stock at a price to the public of $35.50 per share, which amount includes 230,595 shares of common stock sold pursuant to the underwriters' exercise in full of their option to purchase additional shares of common stock to cover over-allotments. HeartWare expects to use the net proceeds of the offering for general corporate and working capital purposes.
J.P. Morgan Securities Inc. acted as the sole book-running manager of the offering, and Canaccord Adams, Lazard Capital Markets and Wedbush PacGrow Life Sciences acted as the co-managers of the offering. The offering was made pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on December 24, 2009, and that was declared effective on January 20, 2010.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. The offering of these securities was made only by means of a prospectus and the related prospectus supplement. You may get these documents for free by visiting EDGAR on the SEC Website at www.sec.gov. Alternatively, copies of the prospectus and the related prospectus supplement can be obtained by contacting J.P. Morgan Securities Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIb and Class IV patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(TM) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare(R) Ventricular Assist System in the European Union. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication.
This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the progress of clinical trials. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in the prospectus and the related prospectus supplement and any other document HeartWare files with the SEC including without limitation those described in "Item 8.01" in HeartWare's Form 8-K filed with the SEC on January 26, 2010.
For further information:
HeartWare International, Inc.
Phone: +1 508 739 0864